Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PCAF/KAT2B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme Domain | PCAF/KAT2B Recombinant Protein (Catalytic Domain & Full-Length). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. | View KAT2B Products |
| Gene Delivery | PCAF/KAT2B Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. HEK293 expressed. | View KAT2B Products |
| Benchmark Ab | Anti-PCAF/KAT2B (Rabbit Recombinant Detection mAb). High-affinity for ELISA, Western Blot, and IF. | View KAT2B Products |
| Validator | PCAF/KAT2B siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View KAT2B Products |
| Related Target: KAT2A/GCN5 | KAT2A (GCN5) Recombinant Protein. Closest paralog HAT; essential for selectivity counter-screening. | View KAT2A Products |
| Related Target: EP300/p300 | EP300 (p300) HAT Domain Protein. Collaborative HAT in transcriptional complexes; key for HAT family selectivity profiling. | View EP300 Products |
| Related Target: CREBBP/CBP | CREBBP (CBP) Recombinant Protein. Functional cousin to EP300; critical for broad HAT panel discrimination. | View CREBBP Products |
Critical Assay Challenges & Technical Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity (KAT2A/GCN5) | Human KAT2A, KAT2B, EP300, and CREBBP recombinant catalytic domains available with >95% purity; sequence verified for true counter-screening. |
| Bromodomain vs HAT Domain Selectivity | Domain-specific truncated recombinant proteins verified by mass spectrometry and theoretical MW for accurate binding/activity studies. |
| Enzymatic Activity Quantification | High-purity HAT domain (>95%) with sequence-verified catalytic site; suitable for acetyltransferase assays using histone H3 substrate. |
| Cellular Target Engagement & Permeability | Lentivirus and siRNA combo for stable overexpression and knockdown; validate compound specificity in native chromatin context. |
| Structural Biology Support | Endotoxin-controlled (<1 EU/ug), low-aggregation formulation suitable for crystallography, SPR, and ITC binding studies. |
Live PCAF/KAT2B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PCAF/KAT2B-targeted epigenetic therapies is intensifying, with major players shifting focus from pan-HAT natural products to highly selective small-molecule inhibitors and targeted protein degraders (PROTACs). As first-generation epigenetic therapies reveal limitations in durable efficacy, the next wave of R&D is targeting dual KAT2A/KAT2B inhibition and bromodomain-specific degradation to overcome compensatory resistance mechanisms in oncology and inflammatory diseases. PCAF/KAT2B is a critical histone acetyltransferase governing transcriptional activation, representing a high-value target in oncology immunoediting and neuroinflammation. Future strategies include allosteric inhibitors and combination therapies with BET inhibitors, PARP inhibitors, or immune checkpoint blockers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Bromodomain) | Preclinical biotech, academic spin-offs | Prostate cancer, immunology | Binding affinity (high-purity Bromodomain proteins needed) |
| Small Molecule (HAT) | Global pharma epigenetic divisions, Crystal Genomics | Solid tumors, inflammation, neurodegeneration, viral HIV | Enzymatic selectivity assay (HAT domain proteins & paralog panels) |
| PROTAC / Degrader | Emerging targeted degradation companies | Solid tumors, leukemia | Cellular degradation assay (lentivirus stable cell lines, full-length proteins) |
| siRNA / ASO | Specialized RNAi firms | Neurodegeneration (Huntington’s, Alzheimer’s) | Knockdown validation (validated siRNA sets) |
| Allosteric Modulator | Early discovery groups | Autoimmune diseases, metabolic | Conformational binding studies (full-length vs domain proteins) |
Gene Aberrations & Clinical Relevance
The KAT2B gene has been found with a mutation (likely uncertain significance) in a patient with isolated coloboma (UniProt VAR_079852), and a known polymorphism (dbSNP:rs17006625) is documented. These variants underscore the need for mutant protein reagents to support functional studies and potential resistance profiling.